PIK3CA and neoplasm: In a prospective analysis, 47% (16/34) of EC patients matched for treatment after NGS combinatorial tumour analysis achieved clinical benefit, including 40% (2/5) of MSI-H patients treated with an immune checkpoint inhibitor and 42% (8/19) of patients matched on the basis of PIK3CA and PTEN mutations (41).